



## **Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis**

May 2, 2022

DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- [Bioventus Inc.](#) (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna® commercial plan members will have access to both [DUROLANE](#) and [GELSYN-3](#), to treat knee osteoarthritis (OA) pain. **DUROLANE**, is a single-injection and **GELSYN-3**, is a three-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. Durolane will be exclusive to all Cigna patients while Gelsyn-3 will be one of two multi-injection HA products under contract.

OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as **DUROLANE** and **GELSYN-3**, help manage knee OA pain.

"We are pleased and excited **DUROLANE** and **GELSYN-3** are among the preferred options available to Cigna® members and physicians," said Tim Donovan, Vice President of Market Access & Health Economics for Bioventus. "Both now have access to two safe HA products that are proven to provide relief from knee OA pain."

### **About Bioventus**

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies and surgical solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit [www.bioventus.com](http://www.bioventus.com), and follow the Company on [LinkedIn](#) and [Twitter](#). Bioventus, the Bioventus logo, GELSYN-3 and DUROLANE are registered trademarks of Bioventus LLC.

### **Media Contact:**

Jamica Whitaker  
Bioventus  
919-666-5770  
[jamica.whitaker@bioventus.com](mailto:jamica.whitaker@bioventus.com)

### **Investor Inquiries:**

Dave Crawford  
Bioventus  
919-474-6787  
[dave.crawford@bioventus.com](mailto:dave.crawford@bioventus.com)